STEVEN ISAACMAN, PH.D.
ANDREW MAHON, PH.D.
Senior Scientist, Medicinal Chemistry | Dr. Mahon received his PhD in Chemistry at Macquarie University, Sydney, Australia, before taking up post-doctoral positions at the California Institute of Technology and New York University. He has gained an expert knowledge of small molecule and peptide synthesis, NMR spectroscopy and protein-protein interaction inhibitor design.
MICHAEL ISAACMAN, PH.D.
Scientist, Medicinal Chemistry | Dr. Isaacman received his Ph.D. from the University of California, Santa Barbara where his research focused on the design and synthesis of silicone-based amphiphilic block co-polymers for drug delivery and personal care. An expert in skin cancer prevention, Dr. Isaacman leads a National Cancer Institute funded project that aims to develop long-wear sunscreens that are more substantive with human skin. Michael has published in the fields of skin care, natural product synthesis, pollutant sensors, and polymer chemistry.
TOM CIRRITO, PH.D.
Corporate Development | Thomas P. Cirrito, Ph.D. is CEO and co-founder of Filament BioSolutions, Inc. a medical and functional foods company focused on evidence-based nutrition. He is also a co-founder of Immunovent, a development stage biotechnology company developing a next-generation, non-invasive allergy diagnostic. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML) since March 2012. Dr. Cirrito joined Stemline in 2005 as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously, he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, MO). He is on the Board of Directors of Antegrin Therapeutics. He currently serves on the Scientific and Business Advisory Board of the Alzheimer’s Drug Discovery Foundation. He is also on the advisory board for New York City’s life science entrepreneurship program, eLabNYC, and serves as a mentor to early stage biotechnology and health care companies. He is an inventor of numerous technologies in oncology, diagnostics, and consumer products.
JAMES CANARY, PH.D.
Scientific Advisory Board Member & Consultant | Dr. James Canary is a professor of chemistry at New York University and leads a research group that uses molecular modeling and organic synthesis to engineer materials with designed properties at the interface between biomedical chemistry and nanoscience. Efforts in the group include the application of stereochemistry to the development of materials for molecular electronics and nanotechnology, drug development projects involving organic catalysts and related compounds, and the design and fabrication of molecular imaging agents for cancer.
INFO@PHDBIOSCIENCES | 646.801.3872 | 14 EAST 4TH STREET, SUITE 811, NEW YORK, NY 10012 ©2016 PHDBIOSCIENCES